Welcome to our dedicated page for INVESTMENT MANAGERS SER TR II news (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on INVESTMENT MANAGERS SER TR II stock.
The SNPX news archive on Stock Titan captures the transition of Synaptogenix, Inc. from a clinical-stage biopharmaceutical company into TAO Synergies Inc., a public company focused on a TAO-centered digital asset treasury strategy. While SNPX was the historical Nasdaq symbol, more recent company communications describe the rebranding to TAO Synergies and the adoption of the new ticker TAOX, with all ongoing stock trading and SEC filings reported under TAOX.
Earlier SNPX news items focus on Synaptogenix’s work in neurodegenerative disease therapeutics. Press releases describe clinical and preclinical studies of the lead candidate Bryostatin-1 in Alzheimer’s disease and preclinical research in Fragile X syndrome, multiple sclerosis, stroke, and traumatic brain injury. Other announcements highlight FDA authorization of an IND for a multiple sclerosis trial at the Cleveland Clinic, a collaboration with LSU Health New Orleans on PUFA analogs for spinal cord injury, and a partnership with Cannasoul Analytics to explore cannabinoid-based therapeutics in several indications.
Later news under the SNPX symbol documents a strategic pivot. In June 2025, Synaptogenix announced a cryptocurrency treasury strategy focused exclusively on the AI-related token TAO, followed by an initial TAO acquisition and the selection of BitGo to provide custody, staking, and trading services. Subsequent releases describe the company’s rebranding to TAO Synergies Inc. and the ticker change to TAOX, with a stated goal of staking TAO for revenue generation and capital appreciation.
By reviewing SNPX news items, readers can trace the company’s evolution from biopharmaceutical research toward a digital asset treasury model and understand the historical context behind the current TAO Synergies (TAOX) profile. For the latest developments, investors should also review news published under the TAOX symbol.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Synaptogenix, Inc. (SNPX) reported promising secondary endpoint results from an NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients. The company has approximately $37.5 million in cash as of December 31, 2022, maintaining a robust financial position. The Phase 2 trial results showed statistical significance in secondary endpoints for the most severe Alzheimer's patient population (MMSE-2 scores of 10-14), indicating potential efficacy. Synaptogenix aims to explore acquisition opportunities and continue collaborations with strategic partners to enhance shareholder value.
Synaptogenix, Inc. (Nasdaq: SNPX) announced topline results from its NIH-sponsored Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease. The trial failed to meet its primary endpoint, showing an average increase in the Severe Impairment Battery (SIB) score of only 1.4 points for the treatment group compared to 0.6 points for the placebo group at week 28. CEO Alan Tuchman expressed disappointment and indicated a review of the trial data to determine next steps. The company remains well-capitalized, holding approximately $38.5 million in cash as of December 15, 2022.